BioSpace News Archive

Monoclonal antibodies have proven to be an important therapeutic option in the ongoing battle against COVID-19.

The Richard King Mellon Foundation has awarded a $100 million gift to the University of Pittsburgh and approved a $150 million grant for Carnegie Mellon University.

Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.

Avrobio’s ex vivo lentiviral gene therapy platform led to durable responses measured in years, and significant reductions in disease-related biomarkers that far exceed today’s standard of care.

BIOVECTRA announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada.

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for omaveloxolone for the treatment of Friedreich’s ataxia.

Antengene Corporation Limited hosted two Investor R&D meetings this week to discuss the Company’s vision and R&D philosophy, strategy, capabilities and its commercial readiness to launch Xpovio® in its markets.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced an update regarding the Phase 2 IMAGINE-DR clinical trial (MK-8507-13), which is evaluating the investigational combination of MK-8507, a non-nucleoside reverse transcriptase inhibitor, and islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, as a once-weekly oral treatment for HIV-1 infection.

Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 185,700 shares of Arcturus’s common stock to 16 newly-hired employees, contingent upon the filing of a Form S-8 Registration Statement.